BN Business News
Add your company to Business Communicator →

Business · 12/10/2011Updated: 10/17/2026 · 1 min read

National Institutes of Health to Grant Exclusive Patent License for Human Anti-Mesothelin Monoclonal Antibodies

The National Institutes of Health is considering granting an exclusive patent license to Sanomab, Ltd. for the development of human anti-mesothelin monoclonal antibodies for the treatment of human cancers, as outlined in several patent applications filed with the US Patent and Trademark Office and other regulatory agencies.

Original source language: Federal Register — Health and Human ServicesOpen original release →

Explore insights

Business insights →